Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Company Overview

Finch Therapeutics Group, Inc. is a clinical-stage biopharmaceutical company developing microbiome-based therapies aimed at treating diseases driven by gut dysbiosis. The company applies a data-driven approach to identify key microbial strains and restore healthy gut function through its proprietary microbial consortia platform. Its lead investigational therapy, RBX2660, is an investigational oral microbiota suspension being evaluated for the prevention of recurrent Clostridioides difficile infection (rCDI).

In addition to RBX2660, Finch is advancing a pipeline of microbiome restoration candidates targeting gastrointestinal and immune-mediated disorders. The company’s technology leverages high-resolution microbial profiling, bioinformatics and manufacturing processes designed to deliver defined biological communities. Early-stage programs include treatments for ulcerative colitis, Crohn’s disease and neurodevelopmental conditions linked to microbiome imbalances.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Finch Therapeutics collaborates with academic institutions, patient advocacy groups and strategic partners to accelerate microbiome therapy development. The organization’s multidisciplinary leadership team brings expertise in microbial ecology, translational medicine and commercial operations. While primarily focused on the U.S. market, Finch has established global research collaborations to explore broader clinical applications of its platform technologies.

Key Stats

• Today's Range: $12.55 to $12.75
• 50-Day Range: $12.75 to $13.75
• 52-Week Range: $1.27 to $15.85
• Volume: 2,542 shs
• Average Volume: 2,135 shs
• Market Capitalization: $20.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Finch Therapeutics Group Stock Analysis - MarketRank™

Finch Therapeutics Group scored higher than 15% of companies evaluated by MarketBeat, and ranked 874th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Finch Therapeutics Group.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Finch Therapeutics Group is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Finch Therapeutics Group is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Finch Therapeutics Group has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Finch Therapeutics Group has been sold short.

Short Interest Ratio / Days to Cover

Finch Therapeutics Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Finch Therapeutics Group has recently decreased by 88.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Finch Therapeutics Group does not currently pay a dividend.

Dividend Growth

Finch Therapeutics Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Finch Therapeutics Group has been sold short.

Short Interest Ratio / Days to Cover

Finch Therapeutics Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Finch Therapeutics Group has recently decreased by 88.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Finch Therapeutics Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.77% of the stock of Finch Therapeutics Group is held by institutions.

FNCH Stock Analysis - Frequently Asked Questions

How have FNCH shares performed this year?

Finch Therapeutics Group's stock was trading at $11.30 on January 1st, 2025. Since then, FNCH stock has increased by 12.8% and is now trading at $12.75.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Wednesday, November, 10th. The company reported ($6.30) EPS for the quarter, topping the consensus estimate of ($12.60) by $6.30. The company earned $11.34 million during the quarter.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Finch Therapeutics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FNCH
• CIK: 1733257
• Web: www.finchtherapeutics.com
• Phone: 617-229-6499
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.14%
• Return on Assets: -26.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.25 per share
• Price / Book: 0.89

Miscellaneous

• Outstanding Shares: 1,606,000
• Free Float: 885,000
• Market Cap: $20.48 million
• Optionable: No Data
• Beta: 1.21